Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2019
GUILFORD, Conn. -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended November 30, 2019. All are available under the Company’s profile on SEDAR at www.sedar.com and on the Company’s website at www.bioasis.us/investors/. Read More
from Financial Post https://ift.tt/2RAuk6i
from Financial Post https://ift.tt/2RAuk6i
Comments
Post a Comment